Methods of treating or preventing serious symptoms from COVID-19 infection
OwnerHenry Winchesterinventor
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.
Claims6
A method for treating or preventing severe Coronavirus Disease 2019 (COVID-19) symptoms in a subject exposed to or infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the method consisting of:
- (i) obtaining a whole blood sample from the subject;
- (ii) quantifying protein levels of at least three of interleukin 6 (IL-6), IL-8, IL-22, and ferritin in the whole blood sample or a serum sample separated therefrom by contacting total protein extracted from the whole blood sample or the serum sample with antibodies specific to IL-6, IL-8, IL-22, and ferritin under conditions suitable for detection of antibody binding to obtain an expression profile, wherein either the antibodies specific to IL-6, IL-8, IL-22, and ferritin or the total protein extracted from the whole blood sample or the serum sample are arrayed on a solid substrate or arrayed in a three-dimensional matrix;
- (iii) determining that the subject compared to a healthy subject has at least three of (1) an increase in IL-6, (2) an increase in IL-8, (3) an increase in IL-22, and (4) an increase or decrease in ferritin expression;
- and
- (iv) administering to the subject a therapeutically effective amount of an anti-inflammatory drug that is a statin.
A method for reducing risk of severe COVID-19 symptoms in a subject exposed to or infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the method consisting of:
- (i) obtaining a whole blood sample from the subject;
- (ii) quantifying protein levels of at least three of interleukin 6 (IL-6), IL-8, IL-22, and ferritin in the whole blood sample or a serum sample separated therefrom by contacting total protein extracted from the whole blood sample or the serum sample with antibodies specific to IL-6, IL-8, IL-22, and ferritin under conditions suitable for detection of antibody binding to obtain an expression profile, wherein either the antibodies specific to IL-6, IL-8, IL-22, and ferritin or the total protein extracted from the whole blood sample or the serum sample are arrayed on a solid substrate or arrayed in a three-dimensional matrix;
- (iii) determining that the subject compared to a healthy subject has at least three of (1) an increase in IL-6, (2) an increase in IL-8, (3) an increase in IL-22, and (4) an increase or decrease in ferritin expression;
- and
- (iv) administering to the subject a therapeutically effective amount of an anti-inflammatory drug that is a statin, whereby the risk of severe COVID-19 symptoms in the subject is reduced.
Dependencies are inferred from the claim text.